B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: Study of 39 cases

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 40-49

  Perry, Anamarija M ^a   Crockett, David ^b   Dave, Bhavana J ^c   Althof, Pamela ^c   Winkler, Lisa ^c   Smith, Lynette M ^d   Aoun, Patricia ^e   Chan, Wing C ^b   Fu, Kai ^b   Greiner, Timothy C ^b   Bierman, Phillip ^b   Gregory Bociek, Robert ^b   Vose, Julie M ^b   Armitage, James O ^b   Weisenburger, Dennis D ^e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BCL2; Burkitt lymphoma; Diffuse large B cell lymphoma; MYC; Unclassifiable B cell lymphoma

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL 6;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA UNCLASSIFIABLE; BCL 2 GENE; BCL 6 GENE; BURKITT LYMPHOMA; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MALE; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; BURKITT LYMPHOMA; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879070639     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12343     Document Type: Article

References (35)

1. Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J. & Kluin, P.M. (2011) Double-hit B-cell lymphomas. Blood, 117, 2319-2331.
2. Carbone, A., Gloghini, A., Aiello, A., Testi, A. & Cabras, A. (2010) B-cell lymphomas with features intermediate between distinct pathologic entities from pathogenesis to pathology. Human Pathology, 41, 621-631.
3. Choi, W.W., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Braziel, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M. & Chan, W.C. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 5494-5502.
4. Corazzelli, G., Frigeri, F., Russo, F., Frairia, C., Arcamone, M., Esposito, G., De Chiara, A., Morelli, E., Capobianco, G., Becchimanzi, C., Volzone, F., Saggese, M., Marcacci, G., De Filippi, R., Vitolo, U. & Pinto, A. (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. British Journal of Haematology, 156, 234-244.
5. Crowley, J. (ed.) (2001) Prognostic Factor Studies. Statistics in Oncology. pp. 321-378. Marcel Dekker, New York.
6. Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.J., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C. & Staudt, L.M. Lymphoma/Leukemia Molecular Profiling Project. (2006) Molecular diagnosis of burkitt's lymphoma. The New England Journal of Medicine, 354, 2431-2442.
7. Dave, B.J., Nelson, M. & Sanger, W.G. (2011) Lymphoma cytogenetics. Clinics in Laboratory Medicine, 31, 725-61, x-xi.
8. Green, T.M., Nielsen, O., de Stricker, K., Xu-Monette, Z.Y., Young, K.H. & Moller, M.B. (2012a) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. The American Journal of Surgical Pathology, 36, 612-619.
9. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Møller, M.B. (2012b) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
10. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
11. Haralambieva, E., Boerma, E.J., van Imhoff, G.W., Rosati, S., Schuuring, E., Muller-Hermelink, H.K., Kluin, P.M. & Ott, G. (2005) Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of burkitt lymphoma. The American Journal of Surgical Pathology, 29, 1086-1094.
12. Hasserjian, R.P., Ott, G., Elenitoba-Johnson, K.S., Balague-Ponz, O., de Jong, D. & de Leval, L. (2009) Commentary on the WHO classification of tumors of lymphoid tissues (2008): 'gray zone' lymphomas overlapping with burkitt lymphoma or classical hodgkin lymphoma. Journal of Hematopathology, 2, 89-95.
13. Hoeller, S. & Copie-Bergman, C. (2012) Grey zone lymphomas: lymphomas with intermediate features. Advances in Hematology, 2012, 460801.
14. Horsman, D.E., Connors, J.M., Pantzar, T. & Gascoyne, R.D. (2001) Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes, Chromosomes & Cancer, 30, 375-382.
15. Hothorn, T., Hornik, K. & Zeileis, A. (2006) Unbiased recursive partitioning: a conditional inference framework. Journal of Computational and Graphical Statistics, 15, 651-674.
16. Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.F., Bernd, H.W., Cogliatti, S.B., Dierlamm, J., Feller, A.C., Hansmann, M.L., Haralambieva, E., Harder, L., Hasenclever, D., Kuhn, M., Lenze, D., Lichter, P., Martin-Subero, J.I., Moller, P., Muller-Hermelink, H.K., Ott, G., Parwaresch, R.M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen, C., Sturzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H.H., Spang, R., Loeffler, M., Trumper, L., Stein, H. & Siebert, R. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. The New England Journal of Medicine, 354, 2419-2430.
17. Iqbal, J., Sanger, W.G., Horsman, D.E., Rosenwald, A., Pickering, D.L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., Sherman, S., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Ott, G., Muller-Hermelink, H.K., Delabie, J., Braziel, R.M., Jaffe, E.S., Campo, E., Lynch, J.C., Connors, J.M., Vose, J.M., Armitage, J.O., Grogan, T.M., Staudt, L.M. & Chan, W.C. (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. The American Journal of Pathology, 165, 159-166.
18. Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. & Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114, 2273-2279.
19. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
20. Leucci, E., Cocco, M., Onnis, A., De Falco, G., van Cleef, P., Bellan, C., van Rijk, A., Nyagol, J., Byakika, B., Lazzi, S., Tosi, P., van Krieken, H. & Leoncini, L. (2008) MYC translocation-negative classical burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. The Journal of Pathology, 216, 440-450.
21. Li, S., Lin, P., Fayad, L.E., Lennon, P.A., Miranda, R.N., Yin, C.C., Lin, E. & Medeiros, L.J. (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH at BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc., 25, 145-156.
22. Lin, P., Dickason, T.J., Fayad, L.E., Lennon, P.A., Hu, P., Garcia, M., Routbort, M.J., Miranda, R., Wang, X., Qiao, W. & Medeiros, L.J. (2012) Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma. Cancer, 118, 1566-1573.
23. McClure, R.F., Remstein, E.D., Macon, W.R., Dewald, G.W., Habermann, T.M., Hoering, A. & Kurtin, P.J. (2005) Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. The American Journal of Surgical Pathology, 29, 1652-1660.
24. Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Braziel, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt, L.M., Chan, W.C. & Weisenburger, D.D. (2011a) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 200-207.
25. Meyer, P.N., Fu, K., Greiner, T., Smith, L., Delabie, J., Gascoyne, R., Ott, G., Rosenwald, A., Braziel, R., Campo, E., Vose, J., Lenz, G., Staudt, L., Chan, W. & Weisenburger, D.D. (2011b) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. American Journal of Clinical Pathology, 135, 54-61.
26. Mossafa, H., Damotte, D., Jenabian, A., Delarue, R., Vincenneau, A., Amouroux, I., Jeandel, R., Khoury, E., Martelli, J.M., Samson, T., Tapia, S., Flandrin, G. & Troussard, X. (2006) Non-hodgkin's lymphomas with burkitt-like cells are associated with c-myc amplification and poor prognosis. Leukemia & Lymphoma, 47, 1885-1893.
27. Perry, A.M., Alvarado-Bernal, Y., Laurini, J.A., Smith, L., Fu, K., Aoun, P., Greiner, T., Chan, W., Bierman, P., Bociek, R.G., Armitage, J., Vose, J. & Weisenburger, D. (2012) Immunostains for C-MYC and BCL2 protein predict survival in patients with diffuse large B-cell lymphoma treated with Rituximab. Modern Pathology, 25, 361A. (USCAP Annual Meeting Abstracts)
28. R Development Core Team (2009) A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. ISBN 3-900051-07-0, URL http://www.R-project.org.
29. Salaverria, I. & Siebert, R. (2011) The gray zone between burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 1835-1843.
30. Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (eds) (2009) An International System for Human Cytogenetic Nomenclature ISCN. Karger, Basel.
31. Slack, G.W. & Gascoyne, R.D. (2011) MYC and aggressive B-cell lymphomas. Advances in Anatomic Pathology, 18, 219-228.
32. Snuderl, M., Kolman, O.K., Chen, Y.B., Hsu, J.J., Ackerman, A.M., Dal Cin, P., Ferry, J.A., Harris, N.L., Hasserjian, R.P., Zukerberg, L.R., Abramson, J.S., Hochberg, E.P., Lee, H., Lee, A.I., Toomey, C.E. & Sohani, A.R. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from burkitt lymphoma and diffuse large B-cell lymphoma. The American Journal of Surgical Pathology, 34, 327-340.
33. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds) (2008) B-cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. pp. 265-266. IARC Press, Lyon.
34. Tapia, G., Lopez, R., Munoz-Marmol, A.M., Mate, J.L., Sanz, C., Marginet, R., Navarro, J.T., Ribera, J.M. & Ariza, A. (2011) Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology, 59, 672-678.
35. Tomita, N., Tokunaka, M., Nakamura, N., Takeuchi, K., Koike, J., Motomura, S., Miyamoto, K., Kikuchi, A., Hyo, R., Yakushijin, Y., Masaki, Y., Fujii, S., Hayashi, T., Ishigatsubo, Y. & Miura, I. (2009) Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica, 94, 935-943.